Phio Pharmaceuticals Corp. (PHIO) key performance indicators and operating metrics (3 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Number of Cutaneous Squamous Cell Carcinoma Patients Treated in Phase 1b Trial (PH-762) | 20.00 | FY2026-Q1 |
| Total Number of Patients Completed Treatment (Phase 1b) | 22.00 | FY2026-Q1 |
| Number of Patients Treated in Phase 1b Trial (PH-762) | 15.00 | FY2025-Q2 |
Back to PHIO overview · PHIO earnings · PHIO holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.